Evidence map›Paper›PMID 32816519›Full record

Trial reportClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B.

Jerzy Windyga, Margarita Timofeeva, Oleksandra Stasyshyn, Vasily Mamonov, José Luis Lamas Castellanos, Toshko Lissitchkov, Krzysztof Chojnowski, Miranda Chapman, Borislava G Pavlova, Srilatha Tangada

Open access · goldAbstract readClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 6 countries.

Jerzy WindygaDepartment of Hemostatic Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, 49564Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Margarita TimofeevaFederal State Budgetary Institution of Science "Kirov Scientific and Research Institute of Hematology and Blood Transfusion of Federal Medico-Biological Agency," Kirov, Russia.
Oleksandra StasyshynInstitute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine.
Vasily MamonovNational Research Center for Hematology, Moscow, Russia.
José Luis Lamas CastellanosHospital Dr. Sotero del Rio, Santiago, Chile.
Toshko LissitchkovNational Center of Hematology, Sofia, Bulgaria.
Krzysztof ChojnowskiDepartment of Hemostasis Disorders, Medical University of Lodz, Lodz, Poland.
Miranda ChapmanBaxalta US Inc, a Takeda company, Cambridge, MA, USA.
Borislava G PavlovaBaxalta Innovations GmbH, a Takeda company, Vienna, Austria.
Srilatha TangadaBaxalta US Inc, a Takeda company, Cambridge, MA, USA.ORCID https://orcid.org/0000-0001-9721-4993
Baxalta (United States) · USComplejo Asistencial Sótero del Río · CLInstitute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine · UAInstytut Hematologii i Transfuzjologi · PLKirov Research Institute of Hematology and Blood Transfusion FMBA · RUMedical University of Lodz · PLNational Medical Research Center for Hematology · RUTakeda (Austria) · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemostatic management is essential for ensuring the safety of patients with hemophilia during surgery. This phase 3, prospective, uncontrolled trial, evaluated hemostatic efficacy, consumption, and safety of a recombinant factor IX concentrate, nonacog gamma (BAX 326, Rixubis

Indexed as

AdolescentAdultAgedBlood Loss, SurgicalChildFactor IXFemaleHemophilia BHemostaticsHumansMaleMiddle AgedPerioperative CarePerioperative PeriodPostoperative HemorrhageProspective StudiesFactor IXHemostaticsRecombinant ProteinsBAX 326hemophilia Bnonacog gammapreviously treated patientsrFIX

Identifiers

PMID32816519
PMCPMC7444148
OpenAlexW3080358800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.